4-(methanesulfonyl-methyl-amino)-piperidine-1-carbonyl chloride | 1119243-78-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-(methanesulfonyl-methyl-amino)-piperidine-1-carbonyl chloride
• 英文别名: 4-(Methanesulfonyl-methyl-amino)-piperidine-1-carbonyl chloride；4-[methyl(methylsulfonyl)amino]piperidine-1-carbonyl chloride
• CAS: 1119243-78-5
• 化学式: C₈H₁₅ClN₂O₃S
• 分子量: 254.738
• InChiKey: XVZFSVIRORXYQC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  66.1
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  N-甲基-N-(哌啶-4-基)甲基磺酰胺 、 三光气 在 吡啶 作用下， 以 二氯甲烷 为溶剂， 以40%的产率得到4-(methanesulfonyl-methyl-amino)-piperidine-1-carbonyl chloride
  参考文献：
  名称：

  PYRROLIDINE ARYL-ETHER AS NK3 RECEPTOR ANTAGONISTS

  摘要：

  该发明涉及一种通式为的化合物，其中Ar、R1、R2、R3、R4、n、o、p、s、X和如本文所定义的或其药用活性盐，包括通式（I）化合物的所有立体异构形式、各个对映异构体和对映体，以及它们的消旋和非消旋混合物。这些化合物是治疗抑郁症、疼痛、精神病、帕金森病、精神分裂症、焦虑和注意力缺陷多动障碍（ADHD）的高潜力NK-3受体拮抗剂。

  公开号：

  US20090054644A1

文献信息

• Pyrrolidine aryl-ether as NK3 receptor antagonists
  申请人：Hoffmann-La Roche Inc.

  公开号：US07812021B2

  公开（公告）日：2010-10-12

  The invention relates to a compound of general formula wherein Ar, R1, R2, R3, R4, n, o, p, s, X and are as defined herein or to a pharmaceutically active salt thereof, including all stereoisomeric forms, individual diastereoisomers and enantiomers of the compound of formula (I) as well as racemic and non-racemic mixtures thereof. The compounds are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).

  本发明涉及一种通式为的化合物，其中Ar，R1，R2，R3，R4，n，o，p，s，X和定义如上，或其药物活性盐，包括公式（I）化合物的所有立体异构体形式，个别对映体和对映体以及它们的外消旋和非外消旋混合物。这些化合物是高潜力的NK-3受体拮抗剂，用于治疗抑郁症、疼痛、精神病、帕金森病、精神分裂症、焦虑症和注意力缺陷多动障碍（ADHD）。
• US7812021B2
  申请人：——

  公开号：US7812021B2

  公开（公告）日：2010-10-12
• [EN] PYRROLIDINE ARYL-ETHER AS NK3 RECEPTOR ANTAGONISTS<br/>[FR] PYRROLIDINE ARYL-ÉTHER EN TANT QU'ANTAGONISTES DES RÉCEPTEURS DE NK3
  申请人：HOFFMANN LA ROCHE

  公开号：WO2009024502A1

  公开（公告）日：2009-02-26

  The invention relates to a compound of general formula (I) wherein is aryl or a five or six membered heteroaryl; is a six to nine membered mono or bi-heterocyclic group, wherein X may be a carbon atom, SO2 or a further hetero atom, selected from the group consisting of N or O; if X is a carbon atom, O, SO2 or unsubstituted N, then R1 is hydrogen, hydroxy, cyano, -(CH 2 ) q -OH, -(CH 2 ) q -NRR', -(CH 2 )q-CN, lower alkyl, -S(O) 2 -lower alkyl, -NR-S(O) 2 -lower alkyl, -C(O)-lower alkyl, -NR-C(O)-lower alkyl, phenyl, or is a heterocyclic group selected from piperidinyl-2-one; if X is a N-atom, substituted by R 1, then R 1 is hydrogen, -(CH 2 ) q -OH, -(CH 2 ) q -NRR', -(CH 2 )q-CN, lower alkyl, -S(O) 2 - lower alkyl, aryl or a five or six membered heteroaryl or -C(O)-lower alkyl, provided that q is 2 or 3. R/R' are independently from each other hydrogen or lower alkyl; R 2 is hydrogen, halogen, lower alkyl, cyano, lower alkoxy substituted by halogen, lower alkyl substituted by halogen or is a five or six membered heteroaryl; R 3 is hydrogen or halogen; R 4 is hydrogen or lower alkyl; n is 1 or 2; in case n is 2, R 1 may be the same or different; o is 1 or 2; in case o is 2, R 2 may be the same or different; p is 1 or 2; in case p is 2, R 3 may be the same or different; q is 1, 2 or 3; s is 0, 1, 2, 3 or 4; or to a pharmaceutically active salt thereof, including all stereoisomeric forms, individual diastereoisomers and enantiomers of the compound of formula (I) as well as racemic and non-racemic mixtures thereof. It has been found that the present compounds are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).
• PYRROLIDINE ARYL-ETHER AS NK3 RECEPTOR ANTAGONISTS
  申请人：Jablonski Philippe

  公开号：US20090054644A1

  公开（公告）日：2009-02-26

  The invention relates to a compound of general formula wherein Ar, R 1 , R 2 , R 3 , R 4 , n, o, p, s, X and are as defined herein or to a pharmaceutically active salt thereof, including all stereoisomeric forms, individual diastereoisomers and enantiomers of the compound of formula (I) as well as racemic and non-racemic mixtures thereof. The compounds are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).

  该发明涉及一种通式为的化合物，其中Ar、R1、R2、R3、R4、n、o、p、s、X和如本文所定义的或其药用活性盐，包括通式（I）化合物的所有立体异构形式、各个对映异构体和对映体，以及它们的消旋和非消旋混合物。这些化合物是治疗抑郁症、疼痛、精神病、帕金森病、精神分裂症、焦虑和注意力缺陷多动障碍（ADHD）的高潜力NK-3受体拮抗剂。